JCAR 020

Drug Profile

JCAR 020

Alternative Names: JCAR020; MUC-16 directed/IL-12 armored T cell therapy - Juno Therapeutics

Latest Information Update: 13 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 07 Jan 2016 Juno Therapeutics and Memorial Sloan Kettering Cancer Center enters into an exclusive license agreement with Eureka Therapeutics for use of a fully-human MUC16 binder in CAR T cell immunotherapy
  • 10 Nov 2015 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 10 Nov 2015 The US FDA approves IND application for MUC-16/IL-12 in Ovarian cancer (recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top